NZ205341A - 37 residue influenza virus peptide and vaccines - Google Patents

37 residue influenza virus peptide and vaccines

Info

Publication number
NZ205341A
NZ205341A NZ205341A NZ20534183A NZ205341A NZ 205341 A NZ205341 A NZ 205341A NZ 205341 A NZ205341 A NZ 205341A NZ 20534183 A NZ20534183 A NZ 20534183A NZ 205341 A NZ205341 A NZ 205341A
Authority
NZ
New Zealand
Prior art keywords
vaccines
residue
influenza virus
virus peptide
peptide
Prior art date
Application number
NZ205341A
Other languages
English (en)
Inventor
N Green
S Alexander
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Priority to NZ22061183A priority Critical patent/NZ220611A/xx
Publication of NZ205341A publication Critical patent/NZ205341A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ205341A 1982-08-23 1983-08-22 37 residue influenza virus peptide and vaccines NZ205341A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ22061183A NZ220611A (en) 1982-08-23 1983-08-22 30 residue influenza virus peptide, vaccines and antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41045582A 1982-08-23 1982-08-23

Publications (1)

Publication Number Publication Date
NZ205341A true NZ205341A (en) 1988-07-28

Family

ID=23624803

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ205341A NZ205341A (en) 1982-08-23 1983-08-22 37 residue influenza virus peptide and vaccines
NZ220612A NZ220612A (en) 1982-08-23 1983-08-22 11 residue influenza virus peptide and vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ220612A NZ220612A (en) 1982-08-23 1983-08-22 11 residue influenza virus peptide and vaccines

Country Status (16)

Country Link
EP (1) EP0116629A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS59501714A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR840006198A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU570929B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK203684A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8505819A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI841583L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR78931B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL69556A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1168636B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO161002C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (2) NZ205341A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH18872A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT77230B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1984000687A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA836080B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR241713A1 (es) * 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
WO1990008161A1 (en) * 1989-01-12 1990-07-26 The Blood Center Of Southeastern Wisconsin Peptide-mediated modulation of t-cell recognition as a means of affecting immune responses
EP0621339B1 (en) * 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
JP2996864B2 (ja) * 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
WO2007134327A2 (en) * 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
US8192927B2 (en) * 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
EP2274334A2 (en) 2008-03-28 2011-01-19 Sea Lane Biotechnologies,llc. Neutralizing molecules to viral antigens
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
JP5780762B2 (ja) 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
JP2012526839A (ja) * 2009-05-13 2012-11-01 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和分子
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
IT1395961B1 (it) * 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
KR20120132506A (ko) * 2010-02-18 2012-12-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신
EP3900740A1 (en) 2010-03-30 2021-10-27 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
EP3446707A1 (en) 2011-12-22 2019-02-27 i2 Pharmaceuticals, Inc. Surrogate binding proteins
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
MX379515B (es) 2012-12-18 2025-03-10 Icahn School Med Mount Sinai Vacunas contra virus de la influenza y sus usos.
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CA3132521A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63224A (en) * 1980-07-17 1985-05-31 Scripps Clinic Res Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom

Also Published As

Publication number Publication date
EP0116629A4 (en) 1987-06-29
IL69556A0 (en) 1983-11-30
PT77230B (en) 1986-02-04
EP0116629A1 (en) 1984-08-29
ES525088A0 (es) 1985-06-16
KR840006198A (ko) 1984-11-22
FI841583A7 (fi) 1984-04-19
PT77230A (en) 1983-09-01
ZA836080B (en) 1984-04-25
IT1168636B (it) 1987-05-20
ES8505819A1 (es) 1985-06-16
DK203684D0 (da) 1984-04-18
AU570929B2 (en) 1988-03-31
NZ220612A (en) 1988-07-28
NO161002B (no) 1989-03-13
PH18872A (en) 1985-10-21
DK203684A (da) 1984-04-18
GR78931B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-10-02
WO1984000687A1 (en) 1984-03-01
IL69556A (en) 1988-05-31
NO841540L (no) 1984-04-17
JPS59501714A (ja) 1984-10-11
NO161002C (no) 1989-06-21
FI841583A0 (fi) 1984-04-19
FI841583L (fi) 1984-04-19
AU1947183A (en) 1984-03-07
IT8348868A0 (it) 1983-08-22

Similar Documents

Publication Publication Date Title
NZ220612A (en) 11 residue influenza virus peptide and vaccines
GB2181435B (en) Recombinant lav/htlv virus and vaccines
PH19997A (en) 20-bpiroxanes and analogues having an open ring e and pharmaceutical preparations thereof
IL61904A (en) Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
JPS6425800A (en) T-cell epitope of hepatities b virus nucleocapside protein
NZ220365A (en) Antiviral peptides and pharmaceutical compositions
GB2212511B (en) Hepatitis c virus
DE3361516D1 (en) Cyanacyl amide derivatives and preparation thereof
IL80895A0 (en) Material and methods for herpes simplex virus vaccination and diagnosis based on gd-2 glycoprotein
IL64847A (en) Immunomodulating phosphorylsubstituted muramylpeptide analogues and pharmaceutical compositions containing them
AU1255383A (en) Foot and mouth disease viral antigenic peptides
ZA864879B (en) Vaccines and diagnostics derived from boving diarrhoea virus
EP0210931A3 (en) Vaccine against varicella-zoster virus
GB2130090B (en) Pharmaceutical preparations and compositions
GB8324970D0 (en) Tripeptide and tetrapeptide alkylamides
NZ221374A (en) Recombinant interferon and compositions containing it
HU901571D0 (en) Vaccine and diagnostics against the virus of pig-cholera
IL89118A0 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
GB8918689D0 (en) 25/15 vaccine
ZA903142B (en) Canine corona virus vaccine
IL79740A0 (en) Hepatitis vaccine
ZA866582B (en) Recombinant virus
NZ220611A (en) 30 residue influenza virus peptide, vaccines and antibodies
GB2181434A (en) Hepatitis b virus vaccine and process for its preparation
ZA837058B (en) Peptide and use thereof